HilleVax's shares rose by 16% in after-hours trading following the announcement of a significant workforce reduction and executive departures. The Boston-based biopharmaceutical company aims to reduce expenses and focus on the development of its norovirus vaccine candidates.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing